Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia

References

• Keating MJ, O'Brien S, Kontoyiannis D, Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43: 1755–1762.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85: 1580–1589.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999;34: 167–170.
   PubMed Web of Science ®Google Scholar
• Thornton PD, Matutes E, Bosanquet AG, High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759–765.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475–476.
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048–2053.
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48: 2412–2417.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Bastien R, Lewis TB, Hawkes JE, High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat 2008;29:757–764.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995;18:493–496.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Smith L, Hackbarth ML, Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63:36–38.
   PubMed Web of Science ®Google Scholar
• Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995;93:73–79.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756–1765.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Byrd JC. Rituximab in chronic lymphocytic leukemia. Semin Hematol 2010;47:156–169.
   PubMed Web of Science ®Google Scholar
• Castro JE, James DF, Sandoval-Sus JD, Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23: 1779–1789.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
   PubMed Web of Science ®Google Scholar
• Roue G, Lopez-Guerra M, Milpied P, Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14:6907–6915.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Alonso R, Lopez-Guerra M, Upshaw R, Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 2009;114:1563–1575.
   PubMed Web of Science ®Google Scholar
• Sher T, Miller KC, Lawrence D, Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85–88.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113:2637–2645.
   PubMed Web of Science ®Google Scholar